octreotide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
peptides and glycopeptides	1980	83150-76-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: octreotide longastatin octreotide acetate sandostatin SMS-201-995 sandostatine	A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula. Molecular weight: 1019.25 Formula: C49H66N10O10S2 CLOGP: 2.53 LIPINSKI: 3 HAC: 20 HDO: 13 TPSA: 332.22 ALOGS: -4.92 ROTB: 17 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

octreotide
longastatin
octreotide acetate
sandostatin
SMS-201-995
sandostatine

A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.

Molecular weight: 1019.25
Formula: C49H66N10O10S2
CLOGP: 2.53
LIPINSKI: 3
HAC: 20
HDO: 13
TPSA: 332.22
ALOGS: -4.92
ROTB: 17

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.70	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	32 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.02 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	2 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.19 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.38 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.35 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company
Aug. 21, 2020	PMDA	Novartis Pharma K.K., Sandoz K.K.
Oct. 21, 1988	FDA	NOVARTIS
Dec. 2, 2022	EMA	AMRYT PHARMACEUTICALS DAC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Needle issue	2100.92	14.26	653	59443	9723	63419203
Blood pressure systolic increased	1279.94	14.26	703	59393	46694	63382232
Body temperature decreased	1014.81	14.26	458	59638	19861	63409065
Malignant neoplasm progression	760.13	14.26	626	59470	81495	63347431
Inappropriate schedule of product administration	741.49	14.26	683	59413	103282	63325644
Blood pressure increased	735.39	14.26	834	59262	161228	63267698
Injection site mass	693.05	14.26	343	59753	18313	63410613
Injection site pain	633.18	14.26	694	59402	129106	63299820
Blood pressure diastolic decreased	486.72	14.26	290	59806	22416	63406510
Syringe issue	379.63	14.26	131	59965	2738	63426188
Blood growth hormone increased	377.79	14.26	88	60008	382	63428544
Heart rate decreased	317.83	14.26	296	59800	45264	63383662
Metastases to liver	296.43	14.26	216	59880	23423	63405503
Flatulence	274.50	14.26	242	59854	34460	63394466
Insulin-like growth factor increased	242.46	14.26	71	60025	848	63428078
Blood pressure diastolic increased	227.95	14.26	133	59963	9877	63419049
Blood chromogranin A increased	225.34	14.26	53	60043	242	63428684
Abdominal pain	224.40	14.26	698	59398	292758	63136168
Second primary malignancy	222.67	14.26	121	59975	7832	63421094
Carcinoid crisis	209.55	14.26	49	60047	217	63428709
Infusion related reaction	208.64	14.26	5	60091	245516	63183410
Abdominal distension	205.09	14.26	325	59771	86290	63342636
Hepatic lesion	201.00	14.26	96	60000	4729	63424197
Mass	191.73	14.26	135	59961	13865	63415061
Rheumatoid arthritis	186.88	14.26	14	60082	253805	63175121
Underdose	184.92	14.26	175	59921	27281	63401645
Stress	184.40	14.26	270	59826	66897	63362029
Cholelithiasis	178.45	14.26	214	59882	43711	63385215
Neoplasm progression	174.09	14.26	193	59903	36235	63392691
Contraindicated product administered	169.16	14.26	9	60087	217639	63211287
Blood pressure decreased	160.86	14.26	249	59847	64773	63364153
Diarrhoea	159.18	14.26	1188	58908	714178	62714748
Drug ineffective	158.37	14.26	488	59608	1044277	62384649
Diabetes mellitus	155.57	14.26	226	59870	55584	63373342
Drug intolerance	154.39	14.26	50	60046	308611	63120315
Injection site discomfort	153.88	14.26	79	60017	4551	63424375
Malaise	150.99	14.26	784	59312	415170	63013756
Toxicity to various agents	144.83	14.26	29	60067	247221	63181705
Weight decreased	144.56	14.26	581	59515	276217	63152709
Intestinal obstruction	143.00	14.26	161	59935	30738	63398188
Injection site haemorrhage	141.36	14.26	143	59953	24171	63404755
Condition aggravated	137.27	14.26	108	59988	402109	63026817
Glossodynia	137.12	14.26	8	60088	178868	63250058
Rash	134.61	14.26	202	59894	560669	62868257
Therapeutic product effect decreased	133.13	14.26	14	60082	193173	63235753
Arthropathy	130.49	14.26	31	60065	234761	63194165
Treatment failure	126.06	14.26	19	60077	199024	63229902
Off label use	121.39	14.26	289	59807	674173	62754753
Completed suicide	119.88	14.26	4	60092	145669	63283257
Flushing	114.94	14.26	233	59863	74854	63354072
Hand deformity	111.29	14.26	11	60085	159446	63269480
Hepatic neoplasm	110.59	14.26	48	60048	1888	63427038
Blood glucose decreased	108.80	14.26	116	59980	20836	63408090
Pericarditis	106.92	14.26	4	60092	131575	63297351
Insulin-like growth factor decreased	106.26	14.26	31	60065	365	63428561
Maternal exposure during pregnancy	105.89	14.26	38	60058	220024	63208902
Bowel movement irregularity	104.40	14.26	64	60032	5200	63423726
Nervousness	102.08	14.26	136	59960	30843	63398083
Blood pressure systolic decreased	100.51	14.26	71	60025	7326	63421600
Neoplasm	98.64	14.26	70	60026	7275	63421651
Acute kidney injury	98.59	14.26	64	60032	263351	63165575
Hypersensitivity	98.00	14.26	80	60016	292605	63136321
Neuroendocrine tumour	97.91	14.26	34	60062	724	63428202
Hepatic pain	95.40	14.26	50	60046	3006	63425920
Drug interaction	92.29	14.26	51	60045	229080	63199846
Intentional product use issue	88.77	14.26	9	60087	127883	63301043
Eating disorder	86.13	14.26	98	59998	18918	63410008
Exposure during pregnancy	85.47	14.26	21	60075	155526	63273400
Metastasis	85.14	14.26	56	60040	5141	63423785
Polyp	84.93	14.26	61	60035	6460	63422466
Pituitary tumour	83.28	14.26	32	60064	916	63428010
Abdominal pain upper	83.03	14.26	401	59695	206043	63222883
Pancreatic neuroendocrine tumour	82.44	14.26	26	60070	405	63428521
Carcinoid syndrome	81.94	14.26	20	60076	110	63428816
Back pain	78.35	14.26	472	59624	263673	63165253
Limb discomfort	77.97	14.26	117	59979	29599	63399327
Serum serotonin increased	77.57	14.26	21	60075	184	63428742
Carcinoid heart disease	77.20	14.26	15	60081	19	63428907
Faeces discoloured	76.49	14.26	91	60005	18418	63410508
Injection site hypersensitivity	76.17	14.26	38	60058	2059	63426867
Terminal state	76.02	14.26	39	60057	2243	63426683
Loss of personal independence in daily activities	75.61	14.26	4	60092	97286	63331640
Death	71.89	14.26	602	59494	373779	63055147
Drug hypersensitivity	69.51	14.26	117	59979	310570	63118356
Sinusitis	68.59	14.26	68	60028	226585	63202341
Overdose	68.37	14.26	13	60083	115065	63313861
Carcinoid tumour	68.24	14.26	22	60074	369	63428557
Hepatic enzyme increased	68.05	14.26	55	60041	202273	63226653
Feeling abnormal	66.06	14.26	297	59799	148095	63280831
Asthenia	63.41	14.26	597	59499	383007	63045919
Cough	62.83	14.26	483	59613	292260	63136666
Impaired healing	62.17	14.26	11	60085	102531	63326395
Hot flush	61.43	14.26	144	59952	51015	63377911
Injection site induration	60.57	14.26	58	60038	9168	63419758
Frequent bowel movements	59.48	14.26	90	60006	22932	63405994
Injection site swelling	59.42	14.26	136	59960	47436	63381490
Nephritic syndrome	59.03	14.26	19	60077	317	63428609
Blood glucose increased	59.00	14.26	194	59902	83562	63345364
Hypoglycaemia	58.40	14.26	156	59940	59909	63369017
Neutropenia	58.31	14.26	48	60048	174957	63253969
Hormone level abnormal	56.54	14.26	33	60063	2450	63426476
Therapeutic product effect incomplete	56.15	14.26	24	60072	125032	63303894
Blood glucose fluctuation	55.50	14.26	41	60055	4535	63424391
Blister	55.04	14.26	27	60069	129787	63299139
Drug abuse	53.31	14.26	4	60092	72514	63356412
Metastases to pancreas	53.08	14.26	17	60079	279	63428647
Rectal polyp	52.67	14.26	25	60071	1214	63427712
Intestinal haemorrhage	52.44	14.26	37	60059	3810	63425116
Blood growth hormone abnormal	51.99	14.26	11	60085	27	63428899
Musculoskeletal stiffness	50.72	14.26	60	60036	184558	63244368
Frustration tolerance decreased	49.84	14.26	46	60050	6942	63421984
Infection	48.77	14.26	89	60007	229084	63199842
Metastases to bone	48.49	14.26	78	60018	20941	63407985
Product dose omission issue	48.10	14.26	93	60003	234220	63194706
Steatorrhoea	48.00	14.26	18	60078	481	63428445
Asthma	47.66	14.26	31	60065	127530	63301396
Thyroid disorder	47.56	14.26	65	60031	15097	63413829
Groin pain	46.91	14.26	53	60043	10150	63418776
Urticaria	46.50	14.26	53	60043	165749	63263177
Product quality issue	46.42	14.26	104	59992	35761	63393165
Influenza	46.42	14.26	215	59881	108507	63320419
Injection site bruising	46.05	14.26	114	59982	41796	63387130
Intentional product misuse	45.82	14.26	3	60093	60914	63368012
Metastases to ovary	45.81	14.26	17	60079	441	63428485
Irritable bowel syndrome	45.50	14.26	11	60085	82401	63346525
Movement disorder	45.42	14.26	77	60019	21584	63407342
Psoriasis	45.36	14.26	13	60083	86944	63341982
Depressed mood	44.88	14.26	110	59986	40081	63388845
Hip fracture	44.52	14.26	91	60005	29383	63399543
Yellow skin	43.38	14.26	27	60069	2253	63426673
Proctalgia	43.15	14.26	40	60056	6070	63422856
Metastases to gastrointestinal tract	43.05	14.26	11	60085	75	63428851
Acne	42.63	14.26	78	60018	23215	63405711
Anxiety	42.29	14.26	351	59745	217190	63211736
Small intestinal obstruction	42.23	14.26	68	60028	18269	63410657
Angina bullosa haemorrhagica	41.87	14.26	12	60084	132	63428794
Adverse event	41.49	14.26	7	60089	67552	63361374
Hepatic mass	41.19	14.26	24	60072	1776	63427150
Productive cough	40.62	14.26	142	59954	63066	63365860
Neuroendocrine tumour of the lung	40.00	14.26	8	60088	13	63428913
Incorrect dose administered	39.65	14.26	136	59960	59832	63369094
Adverse drug reaction	39.63	14.26	13	60083	79701	63349225
Faeces pale	39.58	14.26	23	60073	1694	63427232
White blood cell count decreased	39.51	14.26	44	60052	139060	63289866
Hyponatraemia	39.40	14.26	29	60067	111871	63317055
Change of bowel habit	39.29	14.26	25	60071	2168	63426758
Heart rate increased	39.23	14.26	185	59911	94053	63334873
Febrile neutropenia	38.81	14.26	33	60063	118416	63310510
Seizure	38.72	14.26	41	60055	132593	63296333
Psychiatric symptom	38.45	14.26	35	60061	5188	63423738
Abdominal pain lower	38.45	14.26	79	60017	25599	63403327
Chikungunya virus infection	38.40	14.26	12	60084	181	63428745
Pruritus	38.25	14.26	194	59902	361259	63067667
Muscle swelling	37.73	14.26	15	60081	471	63428455
Blood growth hormone decreased	37.71	14.26	8	60088	20	63428906
5-hydroxyindolacetic acid increased	37.42	14.26	7	60089	6	63428920
Pituitary tumour recurrent	37.42	14.26	10	60086	83	63428843
Depressed level of consciousness	36.89	14.26	7	60089	62071	63366855
Musculoskeletal pain	36.85	14.26	179	59917	92098	63336828
Sciatic nerve injury	36.64	14.26	15	60081	509	63428417
Pollakiuria	36.14	14.26	81	60015	27856	63401070
Fall	36.07	14.26	546	59550	391788	63037138
Nasal discharge discolouration	36.06	14.26	24	60072	2247	63426679
Blood iron decreased	35.85	14.26	56	60040	14665	63414261
Joint swelling	35.74	14.26	174	59922	327492	63101434
Neuropathy peripheral	35.64	14.26	33	60063	113634	63315292
Brain neoplasm	35.61	14.26	31	60065	4335	63424591
Liver injury	35.59	14.26	7	60089	60513	63368413
Pancreatic disorder	35.53	14.26	25	60071	2563	63426363
C-reactive protein increased	35.39	14.26	23	60073	94684	63334242
Musculoskeletal discomfort	35.22	14.26	62	60034	17905	63411021
Alanine aminotransferase increased	35.12	14.26	28	60068	103742	63325184
Adenoma benign	35.03	14.26	17	60079	867	63428059
Gastrointestinal neoplasm	34.79	14.26	13	60083	344	63428582
Decreased appetite	34.79	14.26	377	59719	250675	63178251
Gait disturbance	34.76	14.26	294	59802	182884	63246042
Deep vein thrombosis	34.66	14.26	18	60078	83782	63345144
Injection site warmth	34.52	14.26	56	60040	15139	63413787
Ingrowing nail	34.42	14.26	24	60072	2425	63426501
Gallbladder disorder	34.36	14.26	63	60033	18779	63410147
Pancytopenia	34.28	14.26	25	60071	96908	63332018
Dizziness	34.16	14.26	584	59512	429341	62999585
Crying	33.99	14.26	71	60025	23272	63405654
Injection site hypoaesthesia	33.98	14.26	14	60082	483	63428443
Sensitisation	33.75	14.26	27	60069	3359	63425567
Sleep disorder due to general medical condition, insomnia type	32.99	14.26	5	60091	52212	63376714
Head banging	32.86	14.26	13	60083	403	63428523
Breast mass	32.81	14.26	39	60057	7883	63421043
Mobility decreased	32.60	14.26	40	60056	121119	63307807
Administration site abscess	32.32	14.26	7	60089	20	63428906
Unevaluable event	32.28	14.26	5	60091	51381	63377545
Illness	32.20	14.26	111	59985	48948	63379978
Fibromyalgia	32.20	14.26	18	60078	80402	63348524
Neuroendocrine carcinoma	32.18	14.26	11	60085	223	63428703
Bile duct stone	31.93	14.26	27	60069	3629	63425297
Pain in extremity	31.88	14.26	465	59631	331021	63097905
Metastases to eye	31.81	14.26	10	60086	154	63428772
Administration site induration	31.58	14.26	7	60089	23	63428903
Recurrent cancer	31.55	14.26	21	60075	1966	63426960
Metastases to abdominal cavity	31.54	14.26	13	60083	449	63428477
Buttock injury	31.47	14.26	11	60085	239	63428687
Medication error	30.85	14.26	6	60090	52278	63376648
Skin discolouration	30.65	14.26	92	60004	37736	63391190
Peripheral coldness	30.63	14.26	47	60049	12118	63416808
Respiratory rate increased	30.60	14.26	50	60046	13598	63415328
Administration site discharge	30.51	14.26	7	60089	28	63428898
Polydipsia	30.47	14.26	26	60070	3538	63425388
Facial asymmetry	30.46	14.26	15	60081	790	63428136
Nephrolithiasis	30.22	14.26	98	59998	41886	63387040
Body height increased	30.19	14.26	8	60088	64	63428862
Injection site cyst	30.08	14.26	8	60088	65	63428861
Haemorrhage	30.08	14.26	126	59970	60896	63368030
Wound	29.96	14.26	69	60027	163194	63265732
Injection site scar	29.92	14.26	16	60080	1002	63427924
Multiple sclerosis relapse	29.82	14.26	5	60091	48473	63380453
Blood glucose abnormal	29.68	14.26	37	60059	7855	63421071
Benign neoplasm of adrenal gland	29.58	14.26	7	60089	33	63428893
Hyperhidrosis	29.57	14.26	189	59907	107647	63321279
Cardio-respiratory arrest	29.41	14.26	10	60086	59949	63368977
Blood magnesium decreased	29.11	14.26	48	60048	13150	63415776
Electrocardiogram QT prolonged	29.08	14.26	10	60086	59520	63369406
Oxygen saturation decreased	28.63	14.26	25	60071	88560	63340366
Administration site odour	28.31	14.26	7	60089	41	63428885
Red blood cell sedimentation rate increased	28.27	14.26	4	60092	43978	63384948
Muscle contractions involuntary	28.04	14.26	21	60075	2371	63426555
Metastatic carcinoid tumour	28.00	14.26	6	60090	16	63428910
Pulmonary embolism	27.88	14.26	42	60054	116642	63312284
Ill-defined disorder	27.74	14.26	22	60074	81733	63347193
Anaphylactic reaction	27.63	14.26	14	60082	66086	63362840
Leukopenia	27.25	14.26	20	60076	77270	63351656
Liver abscess	26.84	14.26	22	60074	2832	63426094
Helicobacter infection	26.72	14.26	29	60067	92756	63336170
Furuncle	26.66	14.26	32	60064	6534	63422392
Metastases to fallopian tube	26.53	14.26	7	60089	55	63428871
Biliary obstruction	26.40	14.26	22	60074	2899	63426027
Contusion	25.95	14.26	236	59860	149808	63279118
Neuroendocrine carcinoma metastatic	25.81	14.26	9	60087	194	63428732
Injury	25.76	14.26	19	60077	73228	63355698
Urine odour abnormal	25.72	14.26	31	60065	6358	63422568
Metastases to breast	25.64	14.26	10	60086	298	63428628
Bone pain	25.52	14.26	111	59985	54530	63374396
Hallucination	25.44	14.26	10	60086	54807	63374119
Aspartate aminotransferase increased	25.14	14.26	29	60067	90248	63338678
Chronic obstructive pulmonary disease	25.14	14.26	14	60082	62672	63366254
Chondroma	24.74	14.26	6	60090	32	63428894
Hepatotoxicity	24.70	14.26	3	60093	37038	63391888
Thyroid mass	24.66	14.26	25	60071	4233	63424693
Rhinorrhoea	24.61	14.26	125	59971	65452	63363474
Postoperative wound infection	24.46	14.26	40	60056	10885	63418041
Cardiac failure congestive	24.36	14.26	31	60065	92402	63336524
Screaming	24.29	14.26	22	60074	3240	63425686
Dengue fever	24.18	14.26	12	60084	643	63428283
Injection site vesicles	24	14.26	21	60075	2956	63425970
Pancreatolithiasis	23.61	14.26	9	60087	252	63428674
Breast pain	23.59	14.26	35	60061	8763	63420163
Lactic acidosis	23.43	14.26	4	60092	38283	63390643
Bile output increased	23.22	14.26	6	60090	43	63428883
Swelling	23.15	14.26	159	59937	275219	63153707
Tumour compression	23.10	14.26	6	60090	44	63428882
Tonsillar inflammation	22.88	14.26	7	60089	98	63428828
Pulmonary fibrosis	22.59	14.26	5	60091	39804	63389122
Gout	22.48	14.26	43	60053	13228	63415698
Administration site haemorrhage	22.44	14.26	7	60089	105	63428821
Gastritis fungal	22.44	14.26	7	60089	105	63428821
Biliary colic	22.35	14.26	22	60074	3595	63425331
Muscle strain	22.30	14.26	33	60063	8241	63420685
Periarticular disorder	22.22	14.26	6	60090	52	63428874
Pregnancy	22.21	14.26	4	60092	36832	63392094
Product use in unapproved indication	22.10	14.26	263	59833	178817	63250109
No adverse event	21.94	14.26	6	60090	41399	63387527
Angioedema	21.85	14.26	9	60087	47956	63380970
Pain in jaw	21.78	14.26	7	60089	43489	63385437
Sedation	21.77	14.26	5	60091	38804	63390122
Soft tissue mass	21.72	14.26	9	60087	315	63428611
Metastases to pelvis	21.55	14.26	10	60086	461	63428465
Heart rate irregular	21.55	14.26	58	60038	22363	63406563
Pancreatic enlargement	21.54	14.26	6	60090	59	63428867
Dyspnoea	21.49	14.26	470	59626	660843	62768083
Plasma cell myeloma	21.44	14.26	4	60092	35901	63393025
Small intestine carcinoma	21.43	14.26	10	60086	467	63428459
Injection site inflammation	21.23	14.26	22	60074	3821	63425105
Zinc deficiency	21.10	14.26	6	60090	64	63428862
Diaphragmatic spasm	21.09	14.26	4	60092	4	63428922
Pancreatectomy	21.05	14.26	5	60091	24	63428902
Fear-related avoidance of activities	21.05	14.26	7	60089	130	63428796
Vulval disorder	20.95	14.26	12	60084	860	63428066
Blood gastrin increased	20.88	14.26	5	60091	25	63428901
Urine abnormality	20.38	14.26	29	60067	6990	63421936
Thrombocytopenia	20.33	14.26	74	60022	151083	63277843
Faeces soft	20.31	14.26	26	60070	5666	63423260
Feeling cold	20.21	14.26	59	60037	23829	63405097
Respiratory tract infection	20.20	14.26	7	60089	41476	63387450
Abdominal mass	20.12	14.26	19	60077	2951	63425975
Tumour pain	20.00	14.26	14	60082	1423	63427503
Bone cancer	19.96	14.26	14	60082	1428	63427498
Pallor	19.91	14.26	69	60027	30499	63398427
Suicide attempt	19.91	14.26	17	60079	60901	63368025
Pituitary enlargement	19.84	14.26	5	60091	32	63428894
Large intestine polyp	19.82	14.26	31	60065	8126	63420800
Hypothalamo-pituitary disorder	19.82	14.26	11	60085	742	63428184
Dysstasia	19.59	14.26	54	60042	21112	63407814
Metastases to peritoneum	19.55	14.26	20	60076	3422	63425504
Early satiety	19.47	14.26	12	60084	984	63427942
Metastases to uterus	19.23	14.26	6	60090	90	63428836
Drug-induced liver injury	19.23	14.26	7	60089	40215	63388711
Pancreatic carcinoma recurrent	19.17	14.26	6	60090	91	63428835
Gallbladder neoplasm	19.10	14.26	5	60091	38	63428888
Haemorrhoids	19.02	14.26	55	60041	22095	63406831
Cognitive disorder	18.96	14.26	15	60081	55800	63373126
Treatment noncompliance	18.70	14.26	6	60090	37319	63391607
Bartholinitis	18.66	14.26	5	60091	42	63428884
Lymphatic system neoplasm	18.66	14.26	5	60091	42	63428884
Obesity	18.62	14.26	3	60093	29949	63398977
Nasopharyngitis	18.58	14.26	341	59755	253916	63175010
Back injury	18.50	14.26	33	60063	9627	63419299
Coccydynia	18.32	14.26	14	60082	1629	63427297
Bite	18.31	14.26	9	60087	472	63428454
Gallbladder oedema	18.23	14.26	7	60089	200	63428726
Crystal arthropathy	18.12	14.26	8	60088	328	63428598
Rash maculo-papular	18.11	14.26	4	60092	31892	63397034
Spinal cord injury lumbar	17.97	14.26	5	60091	49	63428877
Abnormal faeces	17.96	14.26	24	60072	5456	63423470
Respiratory failure	17.92	14.26	44	60052	101814	63327112
Urine calcium/creatinine ratio increased	17.92	14.26	6	60090	114	63428812
Alopecia	17.87	14.26	219	59877	337317	63091609
Metastases to bladder	17.75	14.26	7	60089	215	63428711
Cardiac valve disease	17.72	14.26	21	60075	4231	63424695
Application site mass	17.70	14.26	5	60091	52	63428874
Pituitary tumour removal	17.64	14.26	4	60092	15	63428911
Thirst	17.37	14.26	40	60056	14001	63414925
Cyst	17.26	14.26	40	60056	14059	63414867
Carcinoid tumour of the small bowel	17.05	14.26	4	60092	18	63428908
Multiple endocrine neoplasia Type 1	17.05	14.26	4	60092	18	63428908
Myocardial infarction	16.92	14.26	44	60052	99849	63329077
Abortion spontaneous	16.91	14.26	12	60084	47183	63381743
Metastases to spine	16.88	14.26	18	60078	3231	63425695
Insulin-like growth factor abnormal	16.88	14.26	4	60092	19	63428907
Feeling hot	16.85	14.26	93	60003	50261	63378665
Confusional state	16.79	14.26	143	59953	236237	63192689
Respiratory disorder	16.75	14.26	8	60088	39074	63389852
Pneumonia aspiration	16.53	14.26	6	60090	34534	63394392
Endometrial cancer stage I	16.50	14.26	7	60089	260	63428666
Hypokinesia	16.47	14.26	39	60057	13897	63415029
Feeding disorder	16.46	14.26	38	60058	13324	63415602
Overweight	16.42	14.26	19	60077	3732	63425194
Spleen disorder	16.41	14.26	11	60085	1042	63427884
Fear	16.39	14.26	42	60054	15724	63413202
Tumour necrosis	16.35	14.26	10	60086	809	63428117
Body height decreased	16.27	14.26	32	60064	10046	63418880
Constipation	16.19	14.26	301	59795	224642	63204284
Polyuria	16.13	14.26	29	60067	8513	63420413
Memory impairment	16.03	14.26	160	59936	104098	63324828
Oropharyngeal pain	16.01	14.26	148	59948	94339	63334587
Rhabdomyolysis	15.98	14.26	11	60085	43940	63384986
Pituitary tumour benign	15.94	14.26	14	60082	1981	63426945
Musculoskeletal chest pain	15.89	14.26	50	60046	21033	63407893
Hyperglycaemia	15.84	14.26	80	60016	41787	63387139
Vasoactive intestinal polypeptide increased	15.81	14.26	3	60093	3	63428923
Endocrine neoplasm	15.81	14.26	3	60093	3	63428923
Pulse abnormal	15.78	14.26	15	60081	2349	63426577
Trichoglossia	15.74	14.26	7	60089	292	63428634
Gastrointestinal wall thickening	15.74	14.26	12	60084	1392	63427534
Metastases to oesophagus	15.69	14.26	4	60092	27	63428899
Labyrinthitis	15.68	14.26	15	60081	2368	63426558
Insulinoma	15.61	14.26	5	60091	82	63428844
Duodenal ulcer	15.51	14.26	27	60069	7729	63421197
Urethral caruncle	15.50	14.26	5	60091	84	63428842
Erythema	15.48	14.26	243	59853	175508	63253418
Metastases to lung	15.42	14.26	36	60060	12714	63416212
Fatigue	15.35	14.26	1005	59091	887023	62541903
Hyperdynamic left ventricle	15.35	14.26	6	60090	180	63428746
Dysuria	15.34	14.26	68	60028	33670	63395256
Hepatic cancer	15.24	14.26	20	60076	4467	63424459
Pancreatic neuroendocrine tumour metastatic	15.21	14.26	4	60092	31	63428895
Mesenteritis	15.20	14.26	7	60089	317	63428609
Lower respiratory tract infection	15.13	14.26	69	60027	132238	63296688
Short-bowel syndrome	14.97	14.26	8	60088	500	63428426
Arthropod bite	14.96	14.26	27	60069	7951	63420975
Neutrophil count decreased	14.77	14.26	19	60077	56387	63372539
Spinal pain	14.70	14.26	36	60060	13103	63415823
Abdominal neoplasm	14.69	14.26	7	60089	343	63428583
Dysphonia	14.65	14.26	86	60010	47528	63381398
Sepsis	14.61	14.26	85	60011	153038	63275888
Tricuspid valve stenosis	14.60	14.26	3	60093	6	63428920
Muscle neoplasm	14.58	14.26	4	60092	37	63428889
Metastases to lymph nodes	14.52	14.26	27	60069	8131	63420795
Empty sella syndrome	14.39	14.26	4	60092	39	63428887
Plasmablastic lymphoma	14.35	14.26	6	60090	215	63428711
Stomatitis	14.33	14.26	75	60021	138650	63290276

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Needle issue	1423.27	15.08	455	42029	5710	34908737
Blood pressure systolic increased	1205.48	15.08	578	41906	22374	34892073
Body temperature decreased	964.55	15.08	417	42067	12617	34901830
Blood pressure increased	755.99	15.08	716	41768	87386	34827061
Injection site pain	669.26	15.08	475	42009	38530	34875917
Inappropriate schedule of product administration	542.69	15.08	511	41973	61785	34852662
Malignant neoplasm progression	521.90	15.08	587	41897	87459	34826988
Heart rate decreased	402.88	15.08	323	42161	31422	34883025
Blood pressure diastolic decreased	376.17	15.08	195	42289	8899	34905548
Metastases to liver	342.45	15.08	211	42273	13452	34900995
Injection site mass	314.67	15.08	156	42328	6470	34907977
Hepatic neoplasm	245.86	15.08	92	42392	1885	34912562
Blood growth hormone increased	212.03	15.08	56	42428	332	34914115
Blood chromogranin A increased	189.76	15.08	48	42436	233	34914214
Drug interaction	188.04	15.08	26	42458	225920	34688527
Second primary malignancy	185.46	15.08	117	42367	7769	34906678
Hepatic lesion	183.99	15.08	90	42394	3622	34910825
Abdominal pain	172.25	15.08	512	41972	163106	34751341
Syringe issue	171.92	15.08	99	42385	5565	34908882
Acute kidney injury	165.94	15.08	82	42402	304906	34609541
Insulin-like growth factor increased	162.46	15.08	60	42424	1183	34913264
Blood pressure diastolic increased	155.64	15.08	89	42395	4936	34909511
Flushing	154.93	15.08	194	42290	32226	34882221
Malaise	149.92	15.08	531	41953	185294	34729153
Injection site haemorrhage	149.12	15.08	111	42373	9657	34904790
Weight decreased	148.45	15.08	511	41973	175790	34738657
Diarrhoea	141.81	15.08	882	41602	389030	34525417
Carcinoid crisis	140.28	15.08	37	42447	218	34914229
Cholelithiasis	135.23	15.08	147	42337	21001	34893446
Toxicity to various agents	128.17	15.08	42	42442	200320	34714127
Abdominal distension	124.66	15.08	241	42243	58251	34856196
Pain	123.67	15.08	534	41950	204141	34710306
Intestinal obstruction	122.73	15.08	145	42339	22677	34891770
Flatulence	117.84	15.08	137	42347	21061	34893386
Stress	114.81	15.08	162	42322	30185	34884262
Underdose	108.29	15.08	107	42377	13673	34900774
Condition aggravated	105.37	15.08	51	42433	192145	34722302
Febrile neutropenia	102.11	15.08	21	42463	136828	34777619
Off label use	96.10	15.08	232	42252	419292	34495155
Neutropenia	91.55	15.08	38	42446	156740	34757707
Nasopharyngitis	90.21	15.08	236	42248	69732	34844715
Carcinoid syndrome	90.02	15.08	22	42462	90	34914357
Neoplasm	89.93	15.08	65	42419	5402	34909045
5-hydroxyindolacetic acid in urine increased	89.29	15.08	26	42458	231	34914216
Neoplasm progression	89.03	15.08	125	42359	23175	34891272
Blood pressure decreased	81.51	15.08	188	42296	51327	34863120
Injection site swelling	80.52	15.08	84	42400	11443	34903004
Biliary obstruction	75.44	15.08	45	42439	2700	34911747
Injection site discomfort	73.74	15.08	37	42447	1573	34912874
Hormone level abnormal	73.33	15.08	25	42459	386	34914061
Neuroendocrine tumour	71.34	15.08	29	42455	746	34913701
Blood mercury abnormal	69.63	15.08	21	42463	213	34914234
Pancytopenia	68.12	15.08	16	42468	95141	34819306
Pneumonia	67.05	15.08	222	42262	362405	34552042
Faeces soft	65.33	15.08	45	42439	3463	34910984
Metastasis	63.03	15.08	47	42437	4097	34910350
Blood glucose increased	62.73	15.08	201	42283	66517	34847930
Incorrect dose administered	59.88	15.08	144	42340	40371	34874076
Pancreatic neuroendocrine tumour	58.94	15.08	19	42465	244	34914203
Gait disturbance	58.18	15.08	231	42253	84909	34829538
Movement disorder	58.00	15.08	73	42411	12175	34902272
Fatigue	56.68	15.08	693	41791	369960	34544487
Discomfort	54.44	15.08	89	42395	18849	34895598
Serum serotonin increased	53.44	15.08	14	42470	80	34914367
Cardiac failure congestive	52.20	15.08	18	42466	83252	34831195
Heart rate increased	51.41	15.08	148	42336	46195	34868252
Pituitary tumour	51.31	15.08	21	42463	550	34913897
Atrial fibrillation	51.28	15.08	44	42440	122349	34792098
Eating disorder	50.43	15.08	56	42428	8184	34906263
Infusion related reaction	49.40	15.08	4	42480	53053	34861394
Back pain	49.31	15.08	284	42200	121505	34792942
Metastases to pancreas	48.96	15.08	17	42467	278	34914169
Hot flush	48.05	15.08	82	42402	17984	34896463
Thrombocytopenia	47.27	15.08	73	42411	156174	34758273
Blood test abnormal	47.26	15.08	50	42434	6921	34907526
Overdose	47.09	15.08	26	42458	91033	34823414
Steatorrhoea	45.99	15.08	21	42463	722	34913725
Rhinorrhoea	45.43	15.08	98	42386	25570	34888877
Respiratory rate increased	45.31	15.08	58	42426	9836	34904611
Hyponatraemia	45.15	15.08	22	42462	82669	34831778
Sepsis	44.71	15.08	84	42400	166477	34747970
Faecal volume decreased	44.49	15.08	13	42471	117	34914330
Myocardial infarction	44.39	15.08	49	42435	121036	34793411
Respiratory failure	44.31	15.08	40	42444	108532	34805915
Rhabdomyolysis	44.01	15.08	14	42470	68149	34846298
Metastases to bone	43.92	15.08	63	42421	11907	34902540
Heart rate irregular	43.70	15.08	73	42411	15734	34898713
Feeling cold	43.52	15.08	59	42425	10580	34903867
Bowel movement irregularity	43.30	15.08	33	42451	2972	34911475
Asthenia	42.93	15.08	471	42013	244780	34669667
Anaemia	42.91	15.08	143	42341	233192	34681255
Neuropathy peripheral	42.73	15.08	24	42460	83239	34831208
Acute myocardial infarction	42.70	15.08	7	42477	53712	34860735
Diaphragmatic spasm	41.47	15.08	12	42472	104	34914343
Intentional product misuse	40.95	15.08	4	42480	45607	34868840
Erythema	40.58	15.08	214	42270	88566	34825881
Mass	40.46	15.08	49	42435	7856	34906591
Peripheral swelling	39.55	15.08	191	42293	76350	34838097
Intentional product use issue	39.12	15.08	12	42472	59804	34854643
Influenza	39.07	15.08	141	42343	49525	34864922
Coronary artery disease	39.05	15.08	6	42478	48299	34866148
Cardiac arrest	38.55	15.08	36	42448	96123	34818324
Pain in extremity	37.66	15.08	273	42211	126240	34788207
Blood creatine phosphokinase increased	37.60	15.08	5	42479	44852	34869595
Low density lipoprotein decreased	37.43	15.08	21	42463	1122	34913325
Abdominal pain upper	36.65	15.08	178	42306	71312	34843135
Frequent bowel movements	36.62	15.08	60	42424	12727	34901720
Suicide attempt	36.27	15.08	3	42481	39113	34875334
Biliary colic	36.11	15.08	20	42464	1042	34913405
Musculoskeletal chest pain	36.09	15.08	52	42432	9866	34904581
Lacrimal disorder	35.90	15.08	14	42470	322	34914125
Foetal exposure during pregnancy	35.12	15.08	3	42481	38098	34876349
Feeling abnormal	35	15.08	161	42323	63074	34851373
Nerve degeneration	34.58	15.08	12	42472	196	34914251
Bone neoplasm	34.57	15.08	13	42471	270	34914177
Cardio-respiratory arrest	34.54	15.08	12	42472	55261	34859186
Hypoxia	34.36	15.08	12	42472	55083	34859364
Angioedema	34.29	15.08	3	42481	37371	34877076
5-hydroxyindolacetic acid increased	34.28	15.08	6	42478	0	34914447
Product dose omission issue	34.24	15.08	58	42426	119653	34794794
Drug ineffective	34.20	15.08	373	42111	456378	34458069
Blood glucose abnormal	33.95	15.08	39	42445	5913	34908534
Faeces discoloured	33.74	15.08	63	42421	14815	34899632
Product quality issue	33.60	15.08	68	42416	16967	34897480
Interstitial lung disease	33.23	15.08	19	42465	65263	34849184
Necrotising colitis	32.96	15.08	19	42465	1069	34913378
Blood glucose fluctuation	32.88	15.08	32	42452	4012	34910435
Metastases to lymph nodes	32.20	15.08	34	42450	4694	34909753
Neuroendocrine carcinoma metastatic	32.10	15.08	10	42474	114	34914333
Death	32.06	15.08	669	41815	397380	34517067
Nervousness	31.93	15.08	56	42428	12550	34901897
Blood growth hormone abnormal	31.86	15.08	6	42478	3	34914444
Nephrolithiasis	31.83	15.08	95	42389	30238	34884209
Carcinoid heart disease	31.69	15.08	7	42477	16	34914431
Musculoskeletal pain	31.57	15.08	98	42386	31865	34882582
Alanine aminotransferase increased	31.52	15.08	31	42453	80784	34833663
Hyperkalaemia	31.49	15.08	23	42461	69366	34845081
Oropharyngeal pain	30.72	15.08	104	42380	35381	34879066
Abnormal faeces	30.25	15.08	28	42456	3297	34911150
Intra-abdominal fluid collection	29.96	15.08	19	42465	1272	34913175
Terminal state	29.88	15.08	30	42454	3904	34910543
White blood cell count decreased	29.41	15.08	44	42440	95401	34819046
Abdominal discomfort	29.25	15.08	147	42337	59688	34854759
Musculoskeletal discomfort	28.92	15.08	42	42442	8026	34906421
Blood glucose decreased	28.72	15.08	55	42429	13182	34901265
Recurrent cancer	28.71	15.08	19	42465	1368	34913079
Suicidal ideation	28.47	15.08	7	42477	40381	34874066
Metastatic carcinoid tumour	28.05	15.08	6	42478	11	34914436
Deep vein thrombosis	27.87	15.08	23	42461	65225	34849222
Blood growth hormone decreased	27.84	15.08	7	42477	33	34914414
Yellow skin	27.74	15.08	22	42462	2100	34912347
Hepatic pain	27.73	15.08	19	42465	1449	34912998
Hepatic mass	27.19	15.08	17	42467	1110	34913337
Loss of personal independence in daily activities	27.10	15.08	4	42480	33175	34881272
Transfusion-related circulatory overload	26.74	15.08	11	42473	292	34914155
Rash	26.72	15.08	160	42324	222592	34691855
Contusion	26.71	15.08	101	42383	36263	34878184
Polyp	26.53	15.08	28	42456	3864	34910583
Renal mass	26.41	15.08	20	42464	1784	34912663
Seizure	26.28	15.08	55	42429	104802	34809645
Parathyroid hormone-related protein abnormal	26.24	15.08	6	42478	17	34914430
Hernia	26.14	15.08	44	42440	9539	34904908
Neutrophil count decreased	25.82	15.08	15	42469	51089	34863358
Blood potassium decreased	25.73	15.08	63	42421	17852	34896595
Sciatica	25.58	15.08	34	42450	5980	34908467
Concomitant disease aggravated	25.45	15.08	33	42451	5668	34908779
Pulse abnormal	25.44	15.08	17	42467	1244	34913203
Arthralgia	25.43	15.08	317	42167	169724	34744723
Blood creatinine increased	25.36	15.08	48	42436	94928	34819519
Intestinal intraepithelial lymphocytes increased	25.18	15.08	9	42475	161	34914286
Psoriasis	24.99	15.08	8	42476	38804	34875643
Product use in unapproved indication	24.96	15.08	235	42249	117264	34797183
Haematuria	24.87	15.08	15	42469	50051	34864396
Blood urine present	24.72	15.08	46	42438	10788	34903659
Expired product administered	24.51	15.08	25	42459	3316	34911131
Cardiac failure	24.47	15.08	46	42438	91202	34823245
Unevaluable event	24.27	15.08	5	42479	32585	34881862
Chronic kidney disease	23.99	15.08	10	42474	41200	34873247
Decreased appetite	23.94	15.08	308	42176	166084	34748363
Thyroid mass	23.81	15.08	12	42472	515	34913932
Respiratory arrest	23.80	15.08	3	42481	28040	34886407
Hernia pain	23.71	15.08	10	42474	283	34914164
Cortisol free urine increased	23.43	15.08	5	42479	9	34914438
Metastases to gastrointestinal tract	23.12	15.08	7	42477	72	34914375
Chest wall tumour	22.86	15.08	4	42480	0	34914447
Hypertrophic osteoarthropathy	22.62	15.08	7	42477	78	34914369
Injection site oedema	22.49	15.08	9	42475	222	34914225
Cryptitis	22.30	15.08	9	42475	227	34914220
Metastases to thorax	22.24	15.08	6	42478	39	34914408
Metastases to spine	22.05	15.08	21	42463	2563	34911884
Bite	21.71	15.08	7	42477	90	34914357
Neck mass	21.69	15.08	17	42467	1596	34912851
Metastases to oesophagus	21.66	15.08	5	42479	15	34914432
Intestinal metastasis	21.60	15.08	9	42475	247	34914200
Dizziness	21.52	15.08	379	42105	218142	34696305
Therapeutic product effect incomplete	21.35	15.08	18	42466	50523	34863924
Leukopenia	21.34	15.08	27	42457	62829	34851618
Septic shock	21.27	15.08	34	42450	71800	34842647
Mental status changes	20.98	15.08	10	42474	38073	34876374
Eating disorder symptom	20.96	15.08	5	42479	18	34914429
Lactic acidosis	20.96	15.08	8	42476	34764	34879683
Therapeutic product effect decreased	20.93	15.08	8	42476	34735	34879712
Body temperature increased	20.75	15.08	57	42427	17311	34897136
Anxiety	20.68	15.08	198	42286	99230	34815217
Dizziness postural	20.53	15.08	31	42453	6133	34908314
Device occlusion	20.51	15.08	32	42452	6513	34907934
Limb discomfort	20.49	15.08	43	42441	11004	34903443
Saliva altered	20.43	15.08	8	42476	186	34914261
Insulinoma	20.35	15.08	5	42479	21	34914426
Microvillous inclusion disease	20.20	15.08	8	42476	192	34914255
Pancreatic neoplasm	20.17	15.08	13	42471	895	34913552
Cardiogenic shock	20.00	15.08	4	42480	26614	34887833
Scan gallium abnormal	19.98	15.08	5	42479	23	34914424
Ventricular tachycardia	19.96	15.08	4	42480	26575	34887872
Rash maculo-papular	19.92	15.08	5	42479	28446	34886001
Encephalopathy	19.88	15.08	9	42475	35310	34879137
Somnolence	19.76	15.08	69	42415	111047	34803400
Metastases to pelvis	19.75	15.08	9	42475	308	34914139
Pyrexia	19.59	15.08	286	42198	332727	34581720
Eosinophilia	19.58	15.08	4	42480	26218	34888229
Labyrinthitis	19.56	15.08	13	42471	943	34913504
Treatment noncompliance	19.55	15.08	5	42479	28095	34886352
Blood iron decreased	19.54	15.08	28	42456	5285	34909162
Asthma	19.53	15.08	14	42470	42642	34871805
Metastases to lung	19.33	15.08	38	42446	9282	34905165
Disturbance in attention	19.28	15.08	4	42480	25941	34888506
Metastases to spleen	19.22	15.08	10	42474	459	34913988
Probiotic therapy	19.19	15.08	7	42477	133	34914314
Carcinoid tumour	18.85	15.08	8	42476	230	34914217
Injection site bruising	18.80	15.08	36	42448	8627	34905820
Cardiac valve disease	18.75	15.08	21	42463	3097	34911350
Respiratory distress	18.69	15.08	10	42474	35655	34878792
Metastases to eye	18.69	15.08	6	42478	76	34914371
Chills	18.68	15.08	165	42319	80878	34833569
Hallucination	18.67	15.08	21	42463	51477	34862970
Tumour marker increased	18.62	15.08	11	42473	648	34913799
Multiple organ dysfunction syndrome	18.48	15.08	41	42443	76525	34837922
Drug-induced liver injury	18.46	15.08	6	42478	28826	34885621
Depressed level of consciousness	18.42	15.08	15	42469	42826	34871621
Renal failure	18.27	15.08	89	42395	130468	34783979
Renal neoplasm	18.15	15.08	14	42470	1283	34913164
Hypotension	18.14	15.08	177	42307	221472	34692975
Ear discomfort	17.99	15.08	19	42465	2623	34911824
Productive cough	17.84	15.08	92	42392	37721	34876726
Product deposit	17.59	15.08	9	42475	399	34914048
Aggression	17.56	15.08	13	42471	38951	34875496
Apoptosis	17.52	15.08	9	42475	402	34914045
Staphylococcal infection	17.44	15.08	9	42475	32751	34881696
Pancreatic neuroendocrine tumour metastatic	17.40	15.08	6	42478	96	34914351
Acute respiratory distress syndrome	17.36	15.08	5	42479	25964	34888483
High frequency ablation	17.33	15.08	7	42477	177	34914270
Hepatic function abnormal	17.31	15.08	17	42467	44346	34870101
Faeces pale	17.18	15.08	14	42470	1389	34913058
Neuroendocrine tumour of the lung	17.14	15.08	3	42481	0	34914447
Sciatic nerve injury	17.12	15.08	6	42478	101	34914346
Injection site erosion	16.96	15.08	6	42478	104	34914343
Skin warm	16.95	15.08	17	42467	2210	34912237
Gastric hypomotility	16.80	15.08	6	42478	107	34914340
Injection site induration	16.75	15.08	19	42465	2841	34911606
Injection site hypersensitivity	16.49	15.08	8	42476	316	34914131
Gallbladder disorder	16.48	15.08	29	42455	6513	34907934
Ventricular fibrillation	16.13	15.08	4	42480	22950	34891497
Tubulointerstitial nephritis	16.13	15.08	3	42481	21021	34893426
Product prescribing error	16.11	15.08	4	42480	22923	34891524
Biliary tract infection	16.10	15.08	10	42474	645	34913802
Abdominal pain lower	16.06	15.08	38	42446	10533	34903914
Cough	16.06	15.08	264	42220	149876	34764571
Device toxicity	16.06	15.08	4	42480	18	34914429
Eructation	16.05	15.08	24	42460	4707	34909740
Blood cholesterol abnormal	16.03	15.08	15	42469	1791	34912656
Oncologic complication	15.97	15.08	8	42476	339	34914108
Groin pain	15.96	15.08	26	42458	5487	34908960
Hyperoxaluria	15.80	15.08	6	42478	128	34914319
Cytomegalovirus infection	15.77	15.08	6	42478	26129	34888318
Procedural pain	15.76	15.08	24	42460	4782	34909665
Procedural hypertension	15.74	15.08	5	42479	61	34914386
Anaphylactic reaction	15.59	15.08	10	42474	32291	34882156
Swelling of eyelid	15.57	15.08	12	42472	1099	34913348
Electrocardiogram T wave alternans	15.55	15.08	4	42480	21	34914426
Hair colour changes	15.53	15.08	15	42469	1862	34912585
Cerebral infarction	15.44	15.08	7	42477	27448	34886999
Plasma cell myeloma	15.40	15.08	17	42467	42020	34872427
Renal pain	15.38	15.08	19	42465	3109	34911338
Agitation	15.32	15.08	29	42455	57370	34857077
Glycosylated haemoglobin increased	15.31	15.08	39	42445	11321	34903126
Cerebral haemorrhage	15.31	15.08	12	42472	34925	34879522
Arthritis	15.30	15.08	77	42407	31269	34883178
Injection site inflammation	15.29	15.08	11	42473	907	34913540
Nasal congestion	15.27	15.08	62	42422	22995	34891452
Blood pressure fluctuation	15.25	15.08	66	42418	25183	34889264
Feeling hot	15.22	15.08	55	42429	19317	34895130
Nausea	15.08	15.08	529	41955	339379	34575068

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Needle issue	2525.44	13.58	828	89179	12240	79642141
Blood pressure systolic increased	2320.29	13.58	1243	88764	65743	79588638
Body temperature decreased	1889.80	13.58	856	89151	31289	79623092
Blood pressure increased	1477.65	13.58	1485	88522	209875	79444506
Injection site pain	1141.15	13.58	1036	88971	128802	79525579
Inappropriate schedule of product administration	1094.33	13.58	1025	88982	132603	79521778
Malignant neoplasm progression	1056.18	13.58	1013	88994	134977	79519404
Injection site mass	874.67	13.58	436	89571	19748	79634633
Blood pressure diastolic decreased	821.85	13.58	479	89528	29737	79624644
Heart rate decreased	690.54	13.58	598	89409	69718	79584663
Metastases to liver	525.05	13.58	352	89655	27962	79626419
Blood growth hormone increased	467.73	13.58	118	89889	618	79653763
Hepatic lesion	391.75	13.58	180	89827	6779	79647602
Flatulence	361.07	13.58	334	89673	42390	79611991
Blood pressure diastolic increased	354.73	13.58	215	89792	14327	79640054
Insulin-like growth factor increased	330.09	13.58	111	89896	1775	79652606
Second primary malignancy	324.13	13.58	202	89805	14148	79640233
Abdominal pain	319.91	13.58	1066	88941	388503	79265878
Toxicity to various agents	311.91	13.58	51	89956	421489	79232892
Blood chromogranin A increased	306.74	13.58	78	89929	424	79653957
Carcinoid crisis	298.68	13.58	77	89930	446	79653935
Abdominal distension	295.55	13.58	504	89503	119146	79535235
Hepatic neoplasm	292.71	13.58	119	89888	3307	79651074
Stress	283.21	13.58	397	89610	79215	79575166
Injection site haemorrhage	277.35	13.58	239	89768	27631	79626750
Drug interaction	270.25	13.58	68	89939	415115	79239266
Acute kidney injury	260.10	13.58	131	89876	519273	79135108
Completed suicide	256.86	13.58	4	90003	245763	79408618
Cholelithiasis	251.91	13.58	304	89703	52360	79602021
Syringe issue	249.20	13.58	128	89879	6170	79648211
Weight decreased	241.60	13.58	914	89093	354284	79300097
Condition aggravated	239.69	13.58	134	89873	500990	79153391
Off label use	238.06	13.58	413	89594	906802	78747579
Diarrhoea	227.55	13.58	1733	88274	878756	78775625
Blood pressure decreased	227.36	13.58	405	89602	99061	79555320
Malaise	225.31	13.58	1120	88887	488749	79165632
Intestinal obstruction	225.07	13.58	260	89747	42760	79611621
Infusion related reaction	224.37	13.58	8	89999	230229	79424152
Injection site discomfort	207.32	13.58	106	89901	5060	79649321
Mass	205.35	13.58	165	89842	17307	79637074
Flushing	201.20	13.58	359	89648	87909	79566472
Neoplasm progression	190.13	13.58	262	89745	51420	79602961
Underdose	177.86	13.58	203	89804	32948	79621433
Drug abuse	164.50	13.58	4	90003	162687	79491694
Neoplasm	156.25	13.58	108	89899	9008	79645373
Synovitis	155.17	13.58	3	90004	150731	79503650
Drug ineffective	151.37	13.58	668	89339	1080245	78574136
Rheumatoid arthritis	147.94	13.58	28	89979	208442	79445939
Metastasis	143.24	13.58	92	89915	6788	79647593
Neutropenia	141.64	13.58	74	89933	287636	79366745
Diabetes mellitus	135.90	13.58	284	89723	78106	79576275
Carcinoid syndrome	135.09	13.58	34	89973	176	79654205
Neuroendocrine tumour	133.33	13.58	52	89955	1292	79653089
Blood glucose decreased	131.27	13.58	155	89852	26079	79628302
Therapeutic product effect decreased	129.95	13.58	16	89991	163847	79490534
Febrile neutropenia	128.40	13.58	50	89957	230949	79423432
Blood glucose increased	127.30	13.58	350	89657	114625	79539756
Eating disorder	125.25	13.58	135	89872	20562	79633819
Bowel movement irregularity	125.24	13.58	82	89925	6252	79648129
Contraindicated product administered	123.43	13.58	16	89991	157522	79496859
Nervousness	120.79	13.58	168	89839	33247	79621134
Injection site swelling	119.51	13.58	201	89806	46931	79607450
Back pain	119.21	13.58	666	89341	303514	79350867
Intentional product use issue	115.51	13.58	17	89990	152095	79502286
Overdose	110.72	13.58	35	89972	184171	79470210
Pancreatic neuroendocrine tumour	107.44	13.58	37	89970	638	79653743
Drug intolerance	106.70	13.58	85	89922	264034	79390347
Intentional overdose	105.62	13.58	3	90004	105957	79548424
Arthropathy	104.07	13.58	35	89972	177076	79477305
Pituitary tumour	102.87	13.58	42	89965	1180	79653201
Polyp	102.64	13.58	80	89927	8027	79646354
Rash	102.43	13.58	324	89683	578034	79076347
Movement disorder	101.45	13.58	139	89868	27120	79627261
Abdominal pain upper	101.27	13.58	510	89497	223309	79431072
Asthenia	98.62	13.58	945	89062	510744	79143637
Blood pressure systolic decreased	98.22	13.58	89	89918	10987	79643394
Carcinoid heart disease	96.93	13.58	21	89986	47	79654334
Hot flush	96.48	13.58	200	89807	54677	79599704
Fatigue	95.69	13.58	1525	88482	928202	78726179
5-hydroxyindolacetic acid in urine increased	95.49	13.58	27	89980	232	79654149
Treatment failure	94.56	13.58	37	89970	170449	79483932
Hepatic pain	93.66	13.58	58	89949	4014	79650367
Pancytopenia	93.54	13.58	35	89972	165710	79488671
Serum serotonin increased	93.33	13.58	28	89979	302	79654079
Hypersensitivity	93.25	13.58	95	89912	262144	79392237
Faeces discoloured	92.90	13.58	138	89869	28989	79625392
Loss of personal independence in daily activities	92.09	13.58	6	90001	102574	79551807
Hyponatraemia	90.09	13.58	44	89963	177804	79476577
Feeling abnormal	89.07	13.58	386	89621	158813	79495568
Insulin-like growth factor decreased	88.99	13.58	31	89976	554	79653827
Injection site hypersensitivity	87.55	13.58	43	89964	1882	79652499
Gait disturbance	86.36	13.58	462	89545	207044	79447337
Intentional product misuse	84.16	13.58	6	90001	95159	79559222
Nasopharyngitis	83.43	13.58	531	89476	253350	79401031
Glossodynia	82.13	13.58	10	89997	103327	79551054
Heart rate increased	82.08	13.58	311	89696	120413	79533968
Influenza	81.70	13.58	326	89681	129280	79525101
Cough	81.59	13.58	699	89308	366090	79288291
Pericarditis	80.65	13.58	11	89996	104225	79550156
Limb discomfort	80.50	13.58	138	89869	32712	79621669
Blood glucose fluctuation	80.42	13.58	64	89943	6618	79647763
Maternal exposure during pregnancy	80.17	13.58	27	89980	136511	79517870
Metastases to bone	78.29	13.58	116	89891	24311	79630070
Metastases to pancreas	77.82	13.58	28	89979	552	79653829
Frequent bowel movements	77.58	13.58	128	89879	29411	79624970
Hormone level abnormal	77.21	13.58	40	89967	1962	79652419
Steatorrhoea	75.30	13.58	31	89976	890	79653491
Biliary obstruction	74.57	13.58	53	89954	4621	79649760
Injection site induration	73.84	13.58	72	89935	9747	79644634
Hand deformity	73.59	13.58	14	89993	103905	79550476
Exposure during pregnancy	72.96	13.58	13	89994	101119	79553262
Incorrect dose administered	72.92	13.58	221	89786	76409	79577972
Terminal state	72.43	13.58	53	89954	4836	79649545
Cardio-respiratory arrest	71.97	13.58	17	89990	108493	79545888
Respiratory rate increased	71.28	13.58	104	89903	21496	79632885
Alanine aminotransferase increased	71.23	13.58	48	89959	162522	79491859
Blood mercury abnormal	71.16	13.58	21	89986	213	79654168
Product dose omission issue	70.83	13.58	106	89901	247431	79406950
Thrombocytopenia	70.78	13.58	119	89888	265140	79389241
Therapeutic product effect incomplete	70.29	13.58	36	89971	141609	79512772
Faeces soft	70.14	13.58	65	89942	8258	79646123
Nephrolithiasis	69.99	13.58	173	89834	53118	79601263
Musculoskeletal discomfort	69.11	13.58	98	89909	19737	79634644
5-hydroxyindolacetic acid increased	69.02	13.58	13	89994	8	79654373
Respiratory failure	68.41	13.58	62	89945	180849	79473532
Pain in extremity	66.07	13.58	665	89342	363873	79290508
Yellow skin	65.96	13.58	44	89963	3461	79650920
Musculoskeletal pain	65.74	13.58	259	89748	102095	79552286
Groin pain	64.96	13.58	77	89930	13003	79641378
Deep vein thrombosis	62.63	13.58	29	89978	120890	79533491
Cardiac failure congestive	62.44	13.58	42	89965	142360	79512021
Acute myocardial infarction	62.35	13.58	7	90000	77029	79577352
Blood glucose abnormal	62.32	13.58	68	89939	10498	79643883
Rhinorrhoea	61.98	13.58	208	89799	75866	79578515
Acne	61.15	13.58	110	89897	27080	79627301
Heart rate irregular	60.87	13.58	122	89885	32557	79621824
Diaphragmatic spasm	60.09	13.58	16	89991	107	79654274
Drug hypersensitivity	59.70	13.58	158	89849	298758	79355623
Blood iron decreased	59.39	13.58	80	89927	15354	79639027
Feeling cold	59.29	13.58	112	89895	28617	79625764
Angioedema	58.87	13.58	8	89999	76027	79578354
Hepatic enzyme increased	58.49	13.58	72	89935	182538	79471843
Blood growth hormone abnormal	57.77	13.58	13	89994	37	79654344
Asthma	57.70	13.58	41	89966	135054	79519327
Neuropathy peripheral	57.62	13.58	45	89962	141260	79513121
Anxiety	56.98	13.58	477	89530	248035	79406346
White blood cell count decreased	56.44	13.58	78	89929	188210	79466171
Recurrent cancer	56.03	13.58	36	89971	2657	79651724
Depressed level of consciousness	55.21	13.58	20	89987	96632	79557749
Acute respiratory failure	54.90	13.58	3	90004	59538	79594843
Sepsis	54.88	13.58	141	89866	269287	79385094
Dizziness	54.81	13.58	866	89141	525575	79128806
Injection site bruising	54.79	13.58	134	89873	40868	79613513
Blood growth hormone decreased	54.78	13.58	13	89994	50	79654331
Rhabdomyolysis	54.56	13.58	24	89983	103107	79551274
Cardiac arrest	53.92	13.58	69	89938	172027	79482354
Seizure	53.87	13.58	81	89926	188753	79465628
Carcinoid tumour	53.31	13.58	21	89986	536	79653845
Productive cough	53.11	13.58	219	89788	88112	79566269
Sinusitis	52.79	13.58	87	89920	195414	79458967
Psoriasis	52.09	13.58	18	89989	89569	79564812
Impaired healing	52.03	13.58	17	89990	87638	79566743
Oxygen saturation decreased	51.48	13.58	42	89965	129005	79525376
Abdominal pain lower	51.42	13.58	112	89895	31670	79622711
Neuroendocrine tumour of the lung	51.28	13.58	11	89996	23	79654358
Nephritic syndrome	51.21	13.58	19	89988	410	79653971
Pain	51.00	13.58	1094	88913	702708	78951673
Lactic acidosis	50.84	13.58	9	89998	70350	79584031
Anaphylactic reaction	50.14	13.58	16	89991	83727	79570654
Leukopenia	48.92	13.58	36	89971	116477	79537904
Myocardial infarction	48.73	13.58	83	89924	184046	79470335
Contusion	48.70	13.58	311	89696	148465	79505916
Musculoskeletal chest pain	47.98	13.58	94	89913	24670	79629711
Erythema	47.20	13.58	421	89586	222869	79431512
Ingrowing nail	47.08	13.58	33	89974	2814	79651567
Death	46.76	13.58	898	89109	565616	79088765
Hepatic mass	46.68	13.58	31	89976	2420	79651961
Anaemia	46.36	13.58	303	89704	444712	79209669
Faeces pale	46.03	13.58	33	89974	2917	79651464
Neuroendocrine carcinoma metastatic	45.99	13.58	17	89990	363	79654018
Hip fracture	45.95	13.58	105	89902	30656	79623725
Thyroid disorder	45.32	13.58	67	89940	14012	79640369
Unevaluable event	45.11	13.58	5	90002	55580	79598801
Metastases to gastrointestinal tract	44.96	13.58	13	89994	122	79654259
Drug-induced liver injury	44.55	13.58	10	89997	66107	79588274
Interstitial lung disease	44.48	13.58	37	89970	112563	79541818
Suicide attempt	44.34	13.58	19	89988	82913	79571468
Pancreatic disorder	44.00	13.58	34	89973	3368	79651013
Metastases to eye	43.92	13.58	15	89992	252	79654129
Hyperkalaemia	43.48	13.58	39	89968	114359	79540022
Abnormal faeces	43.39	13.58	48	89959	7523	79646858
C-reactive protein increased	43.31	13.58	49	89958	128978	79525403
Metastases to pelvis	43.23	13.58	19	89988	643	79653738
Gallbladder disorder	43.18	13.58	78	89929	19262	79635119
Blood creatine phosphokinase increased	42.56	13.58	11	89996	66079	79588302
Injection site scar	42.09	13.58	20	89987	813	79653568
Decreased appetite	41.73	13.58	579	89428	341839	79312542
Biliary colic	41.49	13.58	35	89972	3927	79650454
Rectal polyp	41.42	13.58	25	89982	1652	79652729
Hypoglycaemia	41.40	13.58	225	89782	101369	79553012
Medication error	41.29	13.58	13	89994	68629	79585752
Sedation	41.29	13.58	5	90002	51890	79602491
Frustration tolerance decreased	40.33	13.58	46	89961	7456	79646925
Red blood cell sedimentation rate increased	40.32	13.58	3	90004	45939	79608442
Fall	40.22	13.58	773	89234	486856	79167525
Faecal volume decreased	40.18	13.58	13	89994	183	79654198
Pulse abnormal	39.84	13.58	32	89975	3352	79651029
Metastases to ovary	39.66	13.58	15	89992	342	79654039
Sciatic nerve injury	39.28	13.58	17	89990	554	79653827
Oropharyngeal pain	39.18	13.58	234	89773	109119	79545262
Toxic epidermal necrolysis	38.87	13.58	3	90004	44578	79609803
Rash maculo-papular	38.77	13.58	8	89999	56070	79598311
Bile duct stone	38.36	13.58	39	89968	5550	79648831
Neutrophil count decreased	38.20	13.58	30	89977	93929	79560452
Bone pain	38.19	13.58	144	89863	55598	79598783
Low density lipoprotein decreased	37.58	13.58	21	89986	1200	79653181
Blister	37.31	13.58	48	89959	119428	79534953
Pneumonia	37.30	13.58	523	89484	659723	78994658
Intestinal haemorrhage	37.28	13.58	41	89966	6385	79647996
Hypoxia	37.12	13.58	37	89970	103206	79551175
Adverse event	36.95	13.58	11	89996	60203	79594178
Urticaria	36.87	13.58	98	89909	185103	79469278
Skin discolouration	36.85	13.58	116	89891	40918	79613463
Bite	36.78	13.58	16	89991	528	79653853
Hallucination	36.64	13.58	26	89981	85719	79568662
Change of bowel habit	36.63	13.58	28	89979	2729	79651652
Coronary artery disease	36.63	13.58	14	89993	65460	79588921
Nasal discharge discolouration	36.60	13.58	27	89980	2494	79651887
Pituitary tumour recurrent	36.33	13.58	12	89995	181	79654200
Respiratory arrest	36.26	13.58	10	89997	57540	79596841
Dyspnoea	35.96	13.58	717	89290	856308	78798073
Adverse drug reaction	35.83	13.58	15	89992	66377	79588004
Multiple sclerosis relapse	35.78	13.58	5	90002	46528	79607853
Cardiac valve disease	35.70	13.58	38	89969	5703	79648678
Respiratory tract infection	35.68	13.58	6	90001	48683	79605698
Metastases to lymph nodes	35.68	13.58	51	89956	10346	79644035
Blood urine present	35.54	13.58	76	89931	21221	79633160
Transfusion-related circulatory overload	35.41	13.58	14	89993	361	79654020
Treatment noncompliance	35.03	13.58	8	89999	52260	79602121
Renal neoplasm	34.91	13.58	24	89983	1984	79652397
Pollakiuria	34.90	13.58	107	89900	37210	79617171
Bone cancer	34.86	13.58	24	89983	1988	79652393
Metastases to oesophagus	34.53	13.58	8	89999	27	79654354
Infection	34.39	13.58	148	89859	241564	79412817
Electrocardiogram QT prolonged	34.12	13.58	31	89976	90355	79564026
Septic shock	33.74	13.58	54	89953	122747	79531634
Injection site hypoaesthesia	33.55	13.58	15	89992	529	79653852
Atrial fibrillation	33.43	13.58	113	89894	197773	79456608
Mental status changes	33.23	13.58	17	89990	66942	79587439
Hyperhidrosis	33.22	13.58	288	89719	151204	79503177
Gout	33.18	13.58	81	89926	24668	79629713
Stevens-Johnson syndrome	33.15	13.58	3	90004	39163	79615218
Abdominal mass	32.45	13.58	29	89978	3516	79650865
Eosinophilia	32.33	13.58	6	90001	45339	79609042
Insulinoma	32.21	13.58	10	89997	122	79654259
Renal mass	31.92	13.58	28	89979	3312	79651069
Muscle strain	31.52	13.58	46	89961	9509	79644872
Nerve degeneration	31.51	13.58	12	89995	279	79654102
Muscle injury	31.43	13.58	8	89999	48553	79605828
Peripheral coldness	31.40	13.58	61	89946	15909	79638472
Thyroid mass	31.40	13.58	30	89977	3960	79650421
Lacrimal disorder	31.28	13.58	14	89993	495	79653886
Urine odour abnormal	31.27	13.58	37	89970	6236	79648145
Labyrinthitis	31.09	13.58	26	89981	2882	79651499
Administration site abscess	31.09	13.58	7	90000	20	79654361
Hernia	30.95	13.58	63	89944	16996	79637385
Blood creatinine increased	30.89	13.58	82	89925	154975	79499406
Drug reaction with eosinophilia and systemic symptoms	30.87	13.58	17	89990	64227	79590154
Injection site cyst	30.70	13.58	9	89998	89	79654292
Chondroma	30.58	13.58	6	90001	6	79654375
Psychotic disorder	30.57	13.58	5	90002	41397	79612984
Sleep disorder due to general medical condition, insomnia type	30.55	13.58	6	90001	43550	79610831
Adenoma benign	30.52	13.58	18	89989	1140	79653241
Pulmonary embolism	30.39	13.58	96	89911	171558	79482823
Metabolic acidosis	30.33	13.58	29	89978	82500	79571881
Chills	30.27	13.58	295	89712	159939	79494442
Respiratory distress	30.19	13.58	14	89993	58325	79596056
Sensitisation	30.13	13.58	27	89980	3284	79651097
Proctalgia	29.92	13.58	46	89961	9955	79644426
Depressed mood	29.77	13.58	121	89886	48359	79606022
Tubulointerstitial nephritis	29.65	13.58	4	90003	38231	79616150
Back injury	29.53	13.58	47	89960	10476	79643905
Buttock injury	29.44	13.58	10	89997	165	79654216
Crying	29.40	13.58	74	89933	22969	79631412
Brain neoplasm	29.31	13.58	34	89973	5612	79648769
Prescribed overdose	29.29	13.58	4	90003	37879	79616502
Illness	29.29	13.58	117	89890	46394	79607987
Administration site discharge	29.28	13.58	7	90000	28	79654353
Pulmonary fibrosis	29.07	13.58	7	90000	44105	79610276
Transaminases increased	29.05	13.58	11	89996	51732	79602649
Acute respiratory distress syndrome	29.02	13.58	7	90000	44060	79610321
Neck mass	28.90	13.58	30	89977	4374	79650007
Administration site induration	28.71	13.58	7	90000	31	79654350
Hepatotoxicity	28.69	13.58	11	89996	51341	79603040
Cyst	28.61	13.58	54	89953	13786	79640595
Colitis ulcerative	28.51	13.58	3	90004	34739	79619642
Multiple organ dysfunction syndrome	28.45	13.58	58	89949	120188	79534193
Tumour marker increased	27.86	13.58	29	89978	4243	79650138
Administration site odour	27.85	13.58	7	90000	36	79654345
Injection site oedema	27.72	13.58	18	89989	1353	79653028
Blood potassium decreased	27.70	13.58	115	89892	46397	79607984
Feeling hot	27.58	13.58	137	89870	59597	79594784
Metastases to spine	27.56	13.58	29	89978	4295	79650086
Musculoskeletal stiffness	27.51	13.58	103	89904	174905	79479476
Liver abscess	27.39	13.58	34	89973	6020	79648361
Insulin-like growth factor abnormal	27.38	13.58	7	90000	39	79654342
Body temperature increased	27.38	13.58	111	89896	44309	79610072
Head banging	27.37	13.58	13	89994	528	79653853
Injection site warmth	27.24	13.58	55	89952	14752	79639629
Pituitary enlargement	27.21	13.58	8	89999	80	79654301
Liver injury	27.17	13.58	15	89992	56599	79597782
Angina bullosa haemorrhagica	27.16	13.58	10	89997	211	79654170
Metastases to lung	27.13	13.58	62	89945	18101	79636280
Aspartate aminotransferase increased	27.10	13.58	74	89933	138567	79515814
Ill-defined disorder	26.82	13.58	21	89986	65854	79588527
Benign neoplasm of adrenal gland	26.80	13.58	7	90000	43	79654338
Concomitant disease aggravated	26.75	13.58	51	89956	13116	79641265
Parathyroid hormone-related protein abnormal	26.68	13.58	6	90001	17	79654364
Pneumonia aspiration	26.45	13.58	22	89985	66945	79587436
Cardiac disorder	26.36	13.58	145	89862	65612	79588769
Osteonecrosis of jaw	26.33	13.58	8	89999	43218	79611163
Pneumocystis jirovecii pneumonia	26.19	13.58	3	90004	32505	79621876
Postoperative wound infection	26.09	13.58	50	89957	12911	79641470
Product quality issue	26.06	13.58	91	89916	33849	79620532
Breast mass	25.97	13.58	35	89972	6719	79647662
Injection site inflammation	25.94	13.58	27	89980	3949	79650432
Hypokalaemia	25.89	13.58	80	89927	143960	79510421
Hernia pain	25.74	13.58	12	89995	467	79653914
Gastrointestinal neoplasm	25.74	13.58	12	89995	467	79653914
Tumour pain	25.51	13.58	21	89986	2278	79652103
Intestinal intraepithelial lymphocytes increased	25.32	13.58	9	89998	171	79654210
Small intestinal obstruction	25.32	13.58	78	89929	27194	79627187
Metastases to fallopian tube	25.31	13.58	7	90000	55	79654326
Irritable bowel syndrome	25.14	13.58	20	89987	62221	79592160
Metastatic carcinoid tumour	25.10	13.58	6	90001	24	79654357
Hepatitis	25.01	13.58	16	89991	55711	79598670
Metastases to abdominal cavity	24.84	13.58	13	89994	651	79653730
Sciatica	24.58	13.58	88	89919	33134	79621247
Bone neoplasm	24.55	13.58	14	89993	832	79653549
Periarticular disorder	24.35	13.58	6	90001	28	79654353
Peripheral swelling	24.12	13.58	433	89574	269184	79385197
Metastases to thorax	24.10	13.58	9	89998	198	79654183
Administration site haemorrhage	23.99	13.58	7	90000	68	79654313
Cerebral haemorrhage	23.97	13.58	18	89989	57655	79596726
Abdominal rigidity	23.89	13.58	23	89984	3065	79651316
Crystal arthropathy	23.76	13.58	9	89998	206	79654175
Polydipsia	23.55	13.58	33	89974	6572	79647809
Product deposit	23.54	13.58	12	89995	569	79653812
Ventricular tachycardia	23.40	13.58	9	89998	41926	79612455
Intra-abdominal fluid collection	23.36	13.58	23	89984	3149	79651232
Injection site haematoma	23.29	13.58	28	89979	4799	79649582
Encephalopathy	23.27	13.58	25	89982	67372	79587009
Chikungunya virus infection	23.17	13.58	9	89998	221	79654160
Anaphylactic shock	23.16	13.58	6	90001	35990	79618391
Abdominal neoplasm	23.01	13.58	12	89995	597	79653784
Agranulocytosis	23.00	13.58	11	89996	45019	79609362
Accidental overdose	22.92	13.58	8	89999	39573	79614808
Glycosylated haemoglobin increased	22.66	13.58	60	89947	19200	79635181
Pallor	22.54	13.58	114	89893	49948	79604433
Hypothalamo-pituitary disorder	22.49	13.58	15	89992	1179	79653202
Facial asymmetry	22.19	13.58	13	89994	813	79653568
Hepatic function abnormal	22.18	13.58	30	89977	73077	79581304
Tumour compression	22.04	13.58	8	89999	162	79654219
Generalised tonic-clonic seizure	22.01	13.58	11	89996	43899	79610482
Psychiatric symptom	21.95	13.58	33	89974	7002	79647379
Bile output increased	21.94	13.58	6	90001	45	79654336
Drug withdrawal syndrome	21.93	13.58	6	90001	34712	79619669
Muscle swelling	21.92	13.58	13	89994	832	79653549
Myelosuppression	21.91	13.58	9	89998	40287	79614094
Mobility decreased	21.85	13.58	68	89939	122107	79532274
Chest injury	21.80	13.58	21	89986	2800	79651581
Tricuspid valve stenosis	21.78	13.58	5	90002	16	79654365
Concomitant disease progression	21.62	13.58	23	89984	3450	79650931
Confusional state	21.61	13.58	242	89765	317755	79336626
Nasal congestion	21.43	13.58	154	89853	76398	79577983
Fear-related avoidance of activities	21.41	13.58	7	90000	102	79654279
Pruritus	21.39	13.58	315	89692	394333	79260048
Hypotension	21.33	13.58	359	89648	439958	79214423
Metastases to breast	21.18	13.58	9	89998	280	79654101
Ventricular fibrillation	21.17	13.58	5	90002	31921	79622460
Cryptitis	20.92	13.58	9	89998	289	79654092
Endocrine neoplasm	20.92	13.58	4	90003	3	79654378
Hepatocellular injury	20.90	13.58	14	89993	47579	79606802
Staphylococcal infection	20.83	13.58	21	89986	58274	79596107
Renal failure	20.80	13.58	137	89870	200831	79453550
Drug dependence	20.76	13.58	10	89997	40759	79613622
Blood test abnormal	20.66	13.58	55	89952	17655	79636726
Cerebral infarction	20.65	13.58	13	89994	45663	79608718
Neutropenic sepsis	20.59	13.58	3	90004	27061	79627320
Pituitary tumour removal	20.53	13.58	5	90002	22	79654359
Renal pain	20.52	13.58	35	89972	8261	79646120
Lymphatic system neoplasm	20.50	13.58	6	90001	59	79654322
Ischaemic stroke	20.42	13.58	6	90001	33125	79621256
Plasma cell myeloma	20.42	13.58	18	89989	53241	79601140
Vasoactive intestinal polypeptide increased	20.38	13.58	4	90003	4	79654377
Hypertrophic osteoarthropathy	20.31	13.58	7	90000	121	79654260
Pancreatolithiasis	20.25	13.58	9	89998	313	79654068
COVID-19 pneumonia	20.18	13.58	4	90003	28845	79625536
Stomatitis	20.17	13.58	91	89916	146666	79507715
Pancreatic neuroendocrine tumour metastatic	20.15	13.58	7	90000	124	79654257
Haematuria	20.13	13.58	29	89978	68807	79585574
Muscle contractions involuntary	20.09	13.58	23	89984	3742	79650639
Liver function test abnormal	20.02	13.58	26	89981	64449	79589932
Urosepsis	20.01	13.58	3	90004	26492	79627889
Blood magnesium decreased	20	13.58	52	89955	16460	79637921
Skin sensitisation	19.96	13.58	13	89994	982	79653399
Product use in unapproved indication	19.95	13.58	395	89612	249964	79404417
International normalised ratio increased	19.92	13.58	41	89966	84680	79569701
Delirium	19.86	13.58	41	89966	84586	79569795
Microvillous inclusion disease	19.86	13.58	8	89999	217	79654164
Neurotoxicity	19.84	13.58	6	90001	32512	79621869
Adrenal insufficiency	19.82	13.58	4	90003	28483	79625898
Prostatomegaly	19.82	13.58	22	89985	3461	79650920
Pulmonary arterial hypertension	19.70	13.58	4	90003	28362	79626019
Suicidal ideation	19.65	13.58	35	89972	76305	79578076
Procedural pain	19.58	13.58	64	89943	23020	79631361
Scan gallium abnormal	19.54	13.58	5	90002	28	79654353
Presyncope	19.53	13.58	11	89996	41043	79613338
Body height increased	19.46	13.58	7	90000	138	79654243
Hyperglycaemia	19.40	13.58	141	89866	70194	79584187
Sluggishness	19.34	13.58	30	89977	6542	79647839
Screaming	19.28	13.58	23	89984	3910	79650471
Dysarthria	19.27	13.58	29	89978	67593	79586788
Tonsillar inflammation	19.27	13.58	7	90000	142	79654239
Bartholinitis	19.10	13.58	5	90002	31	79654350
Hypokinesia	19.10	13.58	56	89951	19004	79635377
Heart valve incompetence	19.09	13.58	21	89986	3270	79651111
Upper respiratory tract infection	19.09	13.58	47	89960	91121	79563260
Ligament sprain	19.05	13.58	45	89962	13419	79640962
Fibromyalgia	18.92	13.58	27	89980	64313	79590068
Metastases to peritoneum	18.90	13.58	24	89983	4348	79650033
Furuncle	18.85	13.58	32	89975	7522	79646859
Abortion spontaneous	18.83	13.58	5	90002	29502	79624879
Subdural haematoma	18.82	13.58	6	90001	31428	79622953
Probiotic therapy	18.78	13.58	7	90000	153	79654228
Serotonin syndrome	18.78	13.58	14	89993	45013	79609368
Coma	18.73	13.58	55	89952	100594	79553787
Arthropod bite	18.70	13.58	34	89973	8437	79645944
Hypersomnia	18.68	13.58	63	89944	23023	79631358
COVID-19	18.67	13.58	103	89904	157571	79496810
Status epilepticus	18.54	13.58	3	90004	25038	79629343
Injection site vesicles	18.52	13.58	20	89987	3052	79651329
Gallbladder neoplasm	18.51	13.58	6	90001	85	79654296
Spinal cord neoplasm	18.43	13.58	9	89998	389	79653992
Acute myeloid leukaemia	18.31	13.58	6	90001	30879	79623502
Mucosal inflammation	18.26	13.58	36	89971	75544	79578837
Empty sella syndrome	18.26	13.58	6	90001	89	79654292
Chronic kidney disease	18.25	13.58	29	89978	66125	79588256
Cytomegalovirus infection	18.12	13.58	13	89994	42631	79611750
Breast pain	18.03	13.58	33	89974	8232	79646149
Metastases to bladder	17.98	13.58	8	89999	279	79654102
Infrequent bowel movements	17.93	13.58	15	89992	1664	79652717
Chronic obstructive pulmonary disease	17.91	13.58	44	89963	85375	79569006
Somnolence	17.80	13.58	178	89829	238803	79415578
Flank pain	17.72	13.58	56	89951	19788	79634593
Limb injury	17.57	13.58	73	89934	29455	79624926
Anorectal discomfort	17.51	13.58	21	89986	3590	79650791
Neuroendocrine carcinoma	17.48	13.58	10	89997	598	79653783
Agitation	17.48	13.58	56	89951	99659	79554722
Rubber sensitivity	17.39	13.58	15	89992	1734	79652647
Somatostatin receptor scan abnormal	17.36	13.58	3	90004	0	79654381
Vulval disorder	17.33	13.58	10	89997	608	79653773
Haemorrhoids	17.33	13.58	72	89935	29056	79625325
Haemorrhage	17.31	13.58	168	89839	90950	79563431
Endometrial cancer stage I	17.30	13.58	7	90000	192	79654189
Face injury	17.26	13.58	21	89986	3643	79650738
Gastrointestinal wall thickening	17.26	13.58	18	89989	2639	79651742
Muscle spasms	17.19	13.58	285	89722	174445	79479936
Cognitive disorder	17.16	13.58	33	89974	69893	79584488
Eructation	17.14	13.58	38	89969	10871	79643510
Small intestine carcinoma	17.11	13.58	12	89995	1024	79653357
Blood cholesterol abnormal	17.10	13.58	20	89987	3330	79651051
Spleen disorder	17.06	13.58	15	89992	1779	79652602
Labelled drug-drug interaction medication error	17.06	13.58	5	90002	27645	79626736
Drug level increased	16.97	13.58	12	89995	39639	79614742
Dysstasia	16.83	13.58	69	89938	27677	79626704
Blood gastrin increased	16.74	13.58	5	90002	53	79654328
Cachexia	16.74	13.58	38	89969	11045	79643336
Fibrous dysplasia of bone	16.73	13.58	4	90003	16	79654365
Skin ulcer	16.65	13.58	22	89985	54128	79600253
Device issue	16.54	13.58	5	90002	27103	79627278
Scar	16.54	13.58	46	89961	15150	79639231
Hypertonic bladder	16.51	13.58	22	89985	4179	79650202
Diabetic ketoacidosis	16.43	13.58	9	89998	34113	79620268
Skin depigmentation	16.37	13.58	12	89995	1098	79653283
Device toxicity	16.35	13.58	4	90003	18	79654363
Dengue fever	16.32	13.58	11	89996	880	79653501
Muscle twitching	16.18	13.58	4	90003	24760	79629621
Product prescribing error	16.17	13.58	16	89991	44797	79609584
Helicobacter infection	16.16	13.58	34	89973	69670	79584711
Apoptosis	16.16	13.58	9	89998	511	79653870
Abdominal adhesions	16.06	13.58	20	89987	3553	79650828
Induration	15.98	13.58	15	89992	1937	79652444
Pituitary tumour benign	15.93	13.58	17	89990	2559	79651822
Injection site erosion	15.90	13.58	6	90001	136	79654245
Subarachnoid haemorrhage	15.89	13.58	4	90003	24461	79629920
Spinal cord injury lumbar	15.89	13.58	5	90002	64	79654317
Bronchiectasis	15.88	13.58	3	90004	22383	79631998
Factor V inhibition	15.82	13.58	8	89999	373	79654008
Intestinal metastasis	15.72	13.58	8	89999	378	79654003
Tension	15.70	13.58	22	89985	4382	79649999
Haemorrhage intracranial	15.68	13.58	5	90002	26188	79628193
Urine abnormality	15.68	13.58	31	89976	8188	79646193
Urine calcium/creatinine ratio increased	15.66	13.58	6	90001	142	79654239
Tachycardia	15.59	13.58	127	89880	177641	79476740
Hyperlipidaemia	15.59	13.58	5	90002	26088	79628293
Polyneuropathy	15.59	13.58	4	90003	24147	79630234
Excessive cerumen production	15.54	13.58	10	89997	740	79653641
Coccydynia	15.53	13.58	15	89992	2006	79652375
Cancer pain	15.52	13.58	24	89983	5221	79649160
Bone marrow failure	15.47	13.58	21	89986	51086	79603295
Injury	15.42	13.58	41	89966	77455	79576926
Aggression	15.37	13.58	21	89986	50937	79603444
Grip strength decreased	15.36	13.58	3	90004	21866	79632515
Cystitis	15.29	13.58	107	89900	52625	79601756
Multiple endocrine neoplasia	15.29	13.58	3	90004	3	79654378
Myocarditis	15.23	13.58	3	90004	21730	79632651
Urethral caruncle	15.22	13.58	5	90002	74	79654307
Cholestasis	15.19	13.58	22	89985	52087	79602294
Leukocytosis	15.13	13.58	16	89991	43439	79610942
Carcinoid tumour of the small bowel	15.07	13.58	7	90000	270	79654111
Device occlusion	15.03	13.58	38	89969	11828	79642553
No adverse event	14.96	13.58	12	89995	37180	79617201
Dystonia	14.90	13.58	3	90004	21396	79632985
Tricuspid valve disease	14.87	13.58	8	89999	424	79653957
Adrenal cyst	14.81	13.58	6	90001	165	79654216
Ear discomfort	14.75	13.58	31	89976	8552	79645829
Hemiparesis	14.71	13.58	10	89997	33723	79620658
Metastases to heart	14.65	13.58	7	90000	288	79654093
Zinc deficiency	14.65	13.58	6	90001	170	79654211
Feeding disorder	14.64	13.58	46	89961	16208	79638173
Cataract	14.61	13.58	120	89887	62000	79592381
Hypohidrosis	14.61	13.58	7	90000	290	79654091
Ataxia	14.60	13.58	5	90002	25034	79629347
Withdrawal syndrome	14.60	13.58	6	90001	26848	79627533
Obesity	14.55	13.58	11	89996	35114	79619267
Renal cyst	14.49	13.58	43	89964	14689	79639692
Injection site pustule	14.48	13.58	5	90002	87	79654294
High frequency ablation	14.47	13.58	7	90000	296	79654085
Swollen tongue	14.46	13.58	16	89991	42554	79611827
Gallbladder oedema	14.43	13.58	7	90000	298	79654083
Metastases to spleen	14.37	13.58	9	89998	635	79653746
Appendicitis	14.30	13.58	3	90004	20791	79633590
Bile output abnormal	14.29	13.58	4	90003	33	79654348
Rib fracture	14.28	13.58	66	89941	27881	79626500
Inguinal hernia	14.27	13.58	26	89981	6462	79647919
Ascites	14.20	13.58	139	89868	75423	79578958
Obstructive airways disorder	14.16	13.58	9	89998	31450	79622931
Emotional disorder	14.15	13.58	42	89965	14345	79640036
Respiratory disorder	14.02	13.58	18	89989	44838	79609543
Biliary tract infection	14.00	13.58	12	89995	1376	79653005
Dysuria	13.97	13.58	102	89905	50849	79603532
Cardiogenic shock	13.97	13.58	16	89991	41898	79612483
Gastritis fungal	13.97	13.58	6	90001	192	79654189
Sputum discoloured	13.93	13.58	55	89952	21688	79632693
Hallucination, visual	13.88	13.58	10	89997	32719	79621662
Disseminated intravascular coagulation	13.88	13.58	12	89995	35830	79618551
Pneumonitis	13.85	13.58	30	89977	60830	79593551
Toxic skin eruption	13.81	13.58	4	90003	22289	79632092
Tooth abscess	13.80	13.58	45	89962	16165	79638216
Kidney infection	13.78	13.58	55	89952	21796	79632585
Saliva altered	13.78	13.58	8	89999	492	79653889
Oncologic complication	13.69	13.58	7	90000	334	79654047
Blood follicle stimulating hormone increased	13.67	13.58	7	90000	335	79654046
Early satiety	13.62	13.58	12	89995	1427	79652954
Dizziness postural	13.61	13.58	36	89971	11513	79642868

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H01CB02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Somatostatin and analogues
FDA MoA	N0000000194	Somatostatin Receptor Agonists
FDA EPC	N0000175904	Somatostatin Analog
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018931	Antineoplastic Agents, Hormonal
MeSH PA	D005765	Gastrointestinal Agents
CHEBI has role	CHEBI:51060	hormone agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Carcinoid syndrome	indication	35868009
Acromegaly	indication	74107003	DOID:2449
Congenital hyperinsulinism	indication	360339005
Diarrhea from Pancreatic VIPoma	indication
Irritable bowel syndrome	off-label use	10743008	DOID:9778
Bleeding esophageal varices	off-label use	17709002	DOID:112
Pancreatic fistula	off-label use	25803005
Short bowel syndrome	off-label use	26629001	DOID:10605
Gastrointestinal fistula	off-label use	37831005
Islet cell hyperplasia	off-label use	42681006	DOID:13317
Non-infective diarrhea	off-label use	69980003
Postgastric surgery syndrome	off-label use	80193009	DOID:8439
Chylothorax	off-label use	83035003
Carcinoid crisis	off-label use	237833006
Insulinoma	off-label use	302822000	DOID:3892
Chemotherapy-Induced Diarrhea	off-label use
Cirrhosis of liver	contraindication	19943007	DOID:5082
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Hypothyroidism	contraindication	40930008	DOID:1459
Renal failure syndrome	contraindication	42399005	DOID:1074
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Intestinal obstruction	contraindication	81060008	DOID:8437
Cobalamin deficiency	contraindication	190634004
Hypoglycemic disorder	contraindication	237630007
Calculus in biliary tract	contraindication	266474003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.29	acidic
pKa2	12.92	acidic
pKa3	13.17	acidic
pKa4	13.77	acidic
pKa5	10.31	Basic
pKa6	7.03	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 20MG BASE	MYCAPSSA	AMRYT	N208232	June 26, 2020	RX	CAPSULE, DELAYED RELEASE	ORAL	8535695	Sept. 17, 2029	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE
EQ 20MG BASE	MYCAPSSA	AMRYT	N208232	June 26, 2020	RX	CAPSULE, DELAYED RELEASE	ORAL	10238709	Feb. 3, 2036	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE
EQ 20MG BASE	MYCAPSSA	AMRYT	N208232	June 26, 2020	RX	CAPSULE, DELAYED RELEASE	ORAL	10695397	Feb. 3, 2036	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE
EQ 20MG BASE	MYCAPSSA	AMRYT	N208232	June 26, 2020	RX	CAPSULE, DELAYED RELEASE	ORAL	11052126	Feb. 3, 2036	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE
EQ 20MG BASE	MYCAPSSA	AMRYT	N208232	June 26, 2020	RX	CAPSULE, DELAYED RELEASE	ORAL	11338011	Feb. 3, 2036	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE
EQ 20MG BASE	MYCAPSSA	AMRYT	N208232	June 26, 2020	RX	CAPSULE, DELAYED RELEASE	ORAL	11510963	Feb. 3, 2036	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE
EQ 20MG BASE	MYCAPSSA	AMRYT	N208232	June 26, 2020	RX	CAPSULE, DELAYED RELEASE	ORAL	11141457	Dec. 28, 2040	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHILE AVOIDING CONCOMITANT ADMINISTRATION OF LEVONORGESTREL

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 20MG BASE	MYCAPSSA	AMRYT	N208232	June 26, 2020	RX	CAPSULE, DELAYED RELEASE	ORAL	June 26, 2023	NEW PRODUCT

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Somatostatin receptor type 5	GPCR	P35346	SSR5_HUMAN	AGONIST	IC50	8.52	WOMBAT-PK	CHEMBL
Somatostatin receptor type 1	GPCR	P30872	SSR1_HUMAN	AGONIST	Ki	6.65	CHEMBL	CHEMBL
Somatostatin receptor type 2	GPCR	P30874	SSR2_HUMAN	AGONIST	EC50	10.70	WOMBAT-PK	CHEMBL
Somatostatin receptor type 3	GPCR	P32745	SSR3_HUMAN	AGONIST	Ki	8.30	WOMBAT-PK	CHEMBL
Somatostatin receptor type 4	GPCR	P31391	SSR4_HUMAN	AGONIST	Ki	6.40	CHEMBL	CHEMBL
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	7.92	PDSP
Somatostatin receptor type 3	GPCR		SSR3_RAT	AGONIST	Ki	7.80	IUPHAR
Somatostatin receptor type 5	GPCR		SSR5_MOUSE	AGONIST	Ki	9.90	IUPHAR
Somatostatin receptor type 2	GPCR		SSR2_MOUSE		IC50	9.55	CHEMBL
Somatostatin receptor type 3	GPCR		SSR3_MOUSE		IC50	8.52	CHEMBL
Somatostatin receptor type 5	GPCR		SSR5_RAT		IC50	8.98	CHEMBL
Somatostatin receptor type 2	GPCR		SSR2_RAT	AGONIST	Ki	8.70	IUPHAR

External reference:

ID	Source
4019864	VUID
N0000147950	NUI
D00442	KEGG_DRUG
79517-01-4	SECONDARY_CAS_RN
4019472	VANDF
4019864	VANDF
C0028833	UMLSCUI
CHEBI:7726	CHEBI
CHEMBL1680	ChEMBL_ID
CHEMBL1200480	ChEMBL_ID
D015282	MESH_DESCRIPTOR_UI
DB00104	DRUGBANK_ID
2055	IUPHAR_LIGAND_ID
5656	INN_ID
RWM8CCW8GP	UNII
448601	PUBCHEM_CID
196457	RXNORM
1443	MMSL
36831	MMSL
5196	MMSL
67607	MMSL
d00370	MMSL
002107	NDDF
004012	NDDF
109053000	SNOMEDCT_US
109055007	SNOMEDCT_US
126155003	SNOMEDCT_US
CHEMBL408687	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Sandostatin	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0180	INJECTION, SOLUTION	50 ug	INTRAVENOUS	NDA	25 sections
Sandostatin	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0180	INJECTION, SOLUTION	50 ug	INTRAVENOUS	NDA	25 sections
Sandostatin	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0180	INJECTION, SOLUTION	50 ug	INTRAVENOUS	NDA	25 sections
Sandostatin	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0181	INJECTION, SOLUTION	100 ug	INTRAVENOUS	NDA	25 sections
Sandostatin	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0181	INJECTION, SOLUTION	100 ug	INTRAVENOUS	NDA	25 sections
Sandostatin	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0181	INJECTION, SOLUTION	100 ug	INTRAVENOUS	NDA	25 sections
Sandostatin	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0182	INJECTION, SOLUTION	500 ug	INTRAVENOUS	NDA	25 sections
Sandostatin	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0182	INJECTION, SOLUTION	500 ug	INTRAVENOUS	NDA	25 sections
Sandostatin	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0182	INJECTION, SOLUTION	500 ug	INTRAVENOUS	NDA	25 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6174	INJECTION, SOLUTION	50 ug	INTRAVENOUS	ANDA	22 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6174	INJECTION, SOLUTION	50 ug	INTRAVENOUS	ANDA	22 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6175	INJECTION, SOLUTION	100 ug	INTRAVENOUS	ANDA	22 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6175	INJECTION, SOLUTION	100 ug	INTRAVENOUS	ANDA	22 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6176	INJECTION, SOLUTION	500 ug	INTRAVENOUS	ANDA	22 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6176	INJECTION, SOLUTION	500 ug	INTRAVENOUS	ANDA	22 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6177	INJECTION, SOLUTION	200 ug	INTRAVENOUS	ANDA	22 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6177	INJECTION, SOLUTION	200 ug	INTRAVENOUS	ANDA	22 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6178	INJECTION, SOLUTION	1000 ug	INTRAVENOUS	ANDA	22 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6178	INJECTION, SOLUTION	1000 ug	INTRAVENOUS	ANDA	22 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3301	INJECTION, SOLUTION	50 ug	INTRAVENOUS	ANDA	23 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3311	INJECTION, SOLUTION	100 ug	INTRAVENOUS	ANDA	23 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3321	INJECTION, SOLUTION	500 ug	INTRAVENOUS	ANDA	23 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3333	INJECTION, SOLUTION	200 ug	INTRAVENOUS	ANDA	23 sections
Octreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3343	INJECTION, SOLUTION	1000 ug	INTRAVENOUS	ANDA	23 sections
OCTREOTIDE ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-685	INJECTION, SOLUTION	200 ug	INTRAVENOUS	ANDA	12 sections
OCTREOTIDE ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-685	INJECTION, SOLUTION	200 ug	INTRAVENOUS	ANDA	12 sections
OCTREOTIDE ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-686	INJECTION, SOLUTION	1000 ug	INTRAVENOUS	ANDA	12 sections
OCTREOTIDE ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-686	INJECTION, SOLUTION	1000 ug	INTRAVENOUS	ANDA	12 sections
OCTREOTIDE ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-687	INJECTION, SOLUTION	50 ug	INTRAVENOUS	ANDA	12 sections
OCTREOTIDE ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-687	INJECTION, SOLUTION	50 ug	INTRAVENOUS	ANDA	12 sections